Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alnylam Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
History of cardiovascular (CV) disease, high CV risk, or estimated glomerular filtration rate (eGFR) ≥30 to \<60 mL/min/1.73m\^2
Mean seated office SBP ≥140 mmHg and ≤170 mmHg
24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM
Must be on stable therapy with 2 to 4 classes of antihypertensive medications
You may not be if
Secondary hypertension
Orthostatic hypotension
Proteinuria \>3 g/day
Serum potassium \>4.8 milliequivalents per liter (mEq/L)
Clareo Health | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
